CHUK (Ab-23) Antibody

What is CHUK (Ab-23) Antibody and what epitope does it recognize?

CHUK (Ab-23) Antibody is a polyclonal antibody produced in rabbit that specifically recognizes the conserved helix-loop-helix ubiquitous kinase alpha (CHUK/IKKα). It targets the peptide sequence around amino acids 21-25 (L-G-T-G-G) derived from Human IKK alpha . This antibody detects endogenous levels of total IKKα protein and has demonstrated reactivity with human, mouse, and rat species . As a polyclonal antibody, it recognizes multiple epitopes on the target protein, which can enhance detection sensitivity compared to monoclonal alternatives.

What is the molecular identity of the CHUK protein targeted by this antibody?

The CHUK protein (also known as IKK-alpha, IKK-A, IKKA, or IKK1) is a ~85 kDa serine/threonine protein kinase identified by UniProt accession number O15111 . It functions as a component of the IκB kinase complex involved in NF-κB signaling pathways. The human CHUK gene is designated by the gene ID 1147 . Understanding the precise molecular identity helps researchers avoid cross-reactivity issues and correctly interpret experimental results.

What are the recommended storage conditions for maintaining antibody activity?

For optimal preservation of activity, CHUK (Ab-23) Antibody should be stored at -20°C or -80°C immediately upon receipt . Repeated freeze-thaw cycles should be avoided as they can cause protein denaturation and loss of binding activity . The antibody is typically supplied at a concentration of 1 mg/mL in phosphate buffered saline (pH 7.4, 150mM NaCl) containing 0.02% sodium azide and 50% glycerol as stabilizers . Researchers should aliquot the antibody upon first thawing to minimize freeze-thaw cycles when conducting multiple experiments over time.

What applications has CHUK (Ab-23) Antibody been validated for?

CHUK (Ab-23) Antibody has been validated for multiple experimental applications including:

The antibody has been successfully tested on various cell lines including HeLa, 293, and 3T3 cells for Western blot applications, and human colon carcinoma tissue for immunohistochemical analysis .

What protocol modifications are recommended for immunohistochemistry with CHUK (Ab-23) Antibody?

When using CHUK (Ab-23) Antibody for immunohistochemistry with formalin-fixed, paraffin-embedded (FFPE) sections, researchers should consider the following protocol modifications:

• Antigen retrieval is critical - heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically recommended

• Use a dilution range of 1:50-1:100 as the starting point

• Include appropriate blocking steps to minimize background staining

• Always include negative controls (no primary antibody and isotype controls) and positive controls (tissues known to express IKKα)

Given the significant concerns about antibody validation in the scientific community, researchers should confirm specific staining patterns by performing blocking experiments with the immunizing peptide as demonstrated in the product data sheet .

What is the optimal protocol for Western blotting with CHUK (Ab-23) Antibody?

For optimal Western blot results with CHUK (Ab-23) Antibody, follow this methodological approach:

• Load 20-30 μg of total protein per lane from whole cell lysates

• Use 8-10% SDS-PAGE to effectively resolve the ~85 kDa IKKα protein

• Transfer proteins to PVDF or nitrocellulose membranes at 100V for 60-90 minutes

• Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Incubate with primary antibody at 1:500-1:1000 dilution overnight at 4°C

• Wash membranes thoroughly with TBST (3 x 10 minutes)

• Incubate with appropriate HRP-conjugated secondary antibody

• Develop using enhanced chemiluminescence detection

Multiple model systems have confirmed the specificity, including extracts from HeLa, 293, and 3T3 cells .

How should researchers validate CHUK (Ab-23) Antibody before experimental use?

Given the widespread inconsistencies in antibody use documented by Johns Hopkins researchers, proper validation of CHUK (Ab-23) Antibody is essential . A comprehensive validation strategy should include:

• Positive and negative control samples: Use cell lines or tissues known to express or lack IKKα

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to confirm specificity

• Genetic approaches: Validate using CHUK knockout or knockdown samples when possible

• Cross-platform validation: Confirm results using orthogonal techniques (e.g., immunofluorescence, flow cytometry)

• Lot-to-lot comparison: Benchmark new lots against previously validated lots

Research by De Marzo and colleagues estimates that at least half of published manuscripts contain potentially incorrect immunohistochemical staining results due to lack of proper antibody validation . Implementing rigorous validation protocols is therefore critical for generating reliable data.

What are the key considerations for distinguishing between research-grade and clinical-grade antibody performance?

Researchers should understand that CHUK (Ab-23) Antibody is a research-grade reagent rather than a clinical-grade antibody. Key differences include:

Johns Hopkins researchers have highlighted that research-grade antibodies are not held to the same validation standards as clinical reagents, leading to potentially $2 billion per year spent on antibodies with questionable reliability . For critical experiments, researchers should consider implementing validation protocols comparable to those used for clinical antibodies.

How can researchers assess batch-to-batch variability in CHUK (Ab-23) Antibody?

To assess batch-to-batch variability:

• Side-by-side comparison: Test new and old antibody lots simultaneously on identical samples

• Quantitative assessment: Compare signal-to-noise ratios and EC50 values in dilution series

• Epitope mapping: Confirm consistent recognition of the target epitope (L-G-T-G-G sequence)

• Documentation: Maintain detailed records of lot numbers and performance characteristics

Researchers should be aware that antibodies purified by affinity-chromatography using epitope-specific peptides, like CHUK (Ab-23) Antibody, may still show variation between production batches .

What are common causes of non-specific binding when using CHUK (Ab-23) Antibody?

When experiencing non-specific binding with CHUK (Ab-23) Antibody, consider these potential causes and solutions:

• Insufficient blocking: Extend blocking time or increase blocking agent concentration

• Excessive antibody concentration: Titrate to determine optimal concentration

• Cross-reactivity with similar epitopes: Perform peptide competition assays

• Buffer composition issues: Adjust salt concentration or detergent levels

• Sample preparation problems: Ensure proper fixation and antigen retrieval methods

The polyclonal nature of CHUK (Ab-23) Antibody means it contains a heterogeneous mixture of antibodies that recognize different epitopes on the target protein, which can occasionally lead to non-specific binding .

How can researchers address protein aggregation issues that might affect antibody performance?

Recent research on bispecific antibodies provides insights applicable to CHUK (Ab-23) Antibody handling. To address potential aggregation issues:

• Centrifuge before use: Remove any aggregates by brief centrifugation

• Optimize buffer conditions: Consider adding stabilizers if aggregation occurs

• Control temperature fluctuations: Maintain consistent temperature during handling

• Minimize agitation stress: Handle samples gently to prevent precipitation

• Assess solution appearance: Monitor for visible precipitation or turbidity

Studies have shown that protein surface hydrophobicity and conformational stability significantly impact aggregation tendency, particularly under agitation stress . If aggregation issues persist, researchers may need to explore alternative buffer formulations or handling protocols.

What experimental design considerations should researchers address when investigating signaling pathway interactions involving CHUK/IKKα?

When designing experiments to study signaling pathways involving CHUK/IKKα:

• Temporal dynamics: Include multiple time points to capture transient interactions

• Stimulation conditions: Test both basal and stimulated states (e.g., with TNFα, IL-1β)

• Subcellular localization: Combine with fractionation or imaging techniques

• Phosphorylation status: Use phospho-specific antibodies alongside total CHUK antibody

• Protein complex analysis: Consider combining with co-immunoprecipitation or proximity ligation assays

Researchers should recognize that as part of the IKK complex, CHUK/IKKα interacts with multiple proteins including IKBKB (IKKβ) and IKBKG (NEMO), making experimental design particularly important for accurately characterizing its functional role in signaling cascades.

How should researchers interpret variations in CHUK/IKKα detection across different experimental systems?

When interpreting variations in CHUK/IKKα detection:

• Expression level differences: Consider basal expression levels in different cell types

• Post-translational modifications: Assess impact of phosphorylation on epitope accessibility

• Protein interactions: Evaluate whether protein-protein interactions mask epitopes

• Technical variables: Account for differences in sample preparation and detection methods

• Antibody specificity: Consider cross-reactivity with related proteins (e.g., IKKβ)

Integration of results from multiple experimental approaches helps build confidence in observations and mitigates the risk of antibody-specific artifacts .

What steps can researchers take to improve reproducibility when using CHUK (Ab-23) Antibody?

To enhance reproducibility:

• Detailed methods reporting: Document all experimental conditions, including antibody catalog number, lot, dilution, and incubation parameters

• Validation data sharing: Include antibody validation data in publications

• Resource identification: Use Research Resource Identifiers (RRIDs) for antibodies

• Replication strategy: Perform biological replicates across different days and antibody lots

• Controls implementation: Include appropriate positive, negative, and technical controls

The widespread inconsistencies in immunohistochemical staining highlighted by Johns Hopkins researchers emphasize the critical importance of these reproducibility measures .

What emerging methodologies might complement or enhance experiments using CHUK (Ab-23) Antibody?

Emerging methodologies that can complement CHUK (Ab-23) Antibody-based experiments include:

• Proximity labeling techniques: BioID or APEX2 to identify interacting proteins

• Single-cell analysis: Combining with single-cell sequencing for heterogeneity assessment

• Super-resolution microscopy: For detailed subcellular localization studies

• CRISPR-based approaches: For precise endogenous tagging of CHUK

• Proteomics integration: Combining with mass spectrometry for comprehensive analysis

These approaches can provide complementary data that addresses some limitations of traditional antibody-based methods and enhances experimental rigor.

How might improvements in antibody validation standards affect future research using CHUK (Ab-23) Antibody?

The push for improved antibody validation standards, as advocated by Johns Hopkins researchers, will likely impact future research using CHUK (Ab-23) Antibody in several ways :

• Enhanced reproducibility: More consistent results across laboratories

• Reduced waste: Less time and resources spent on troubleshooting

• Higher confidence: Greater trust in published findings

• Improved comparison: Better ability to compare results across studies

• Method standardization: Development of optimized, validated protocols

Industry-wide adoption of standardized validation practices would address the estimated $2 billion per year spent on antibody experiments with potentially unreliable results .